title: Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
abstract: OBJECTIVE
  To report our results with accelerated partial breast irradiation (APBI) in terms of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2/neu) status.
  
  
  METHODS
  Between February 2003 and June 2009, 209 women with early-stage breast carcinomas were treated with APBI using multicatheter, MammoSite, or Contura brachytherapy to 34 Gy in 10 fractions twice daily over 5-7 days. Three patient groups were defined by receptor status: Group 1: ER or PR (+) and HER-2/neu (-) (n = 180), Group 2: ER and PR (-) and HER-2/neu (+) (n = 10), and Group 3: ER, PR, and HER-2/neu (-) (triple negative breast cancer, n = 19). Median follow-up was 22 months.
  
  
  RESULTS
  Group 3 patients had significantly higher Scarff-Bloom-Richardson scores (p < 0.001). The 3-year ipsilateral breast tumor control rates for Groups 1, 2, and 3 were 99%, 100%, and 100%, respectively (p = 0.15). Group 3 patients tended to experience relapse in distant sites earlier than did non-Group 3 patients. The 3-year relapse-free survival rates for Groups 1, 2, and 3 were 100%, 100%, and 81%, respectively (p = 0.046). The 3-year cause-specific and overall survival rates for Groups 1, 2, and 3 were 100%, 100%, and 89%, respectively (p = 0.002).
  
  
  CONCLUSIONS
  Triple negative breast cancer patients typically have high-grade tumors with significantly worse relapse-free, cause-specific, and overall survival. Longer follow-up will help to determine whether these patients also have a higher risk of ipsilateral breast tumor relapse.
authors.affiliation: Cancer Center of Irvine, Irvine, CA 92618, USA.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Wilder
authors.forename: Lisa D
authors.initials: LD
authors.lastname: Curcio
authors.forename: Rajesh K
authors.initials: RK
authors.lastname: Khanijou
authors.forename: Martin E
authors.initials: ME
authors.lastname: Eisner
authors.forename: Jane L
authors.initials: JL
authors.lastname: Kakkis
authors.forename: Lucy
authors.initials: L
authors.lastname: Chittenden
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Agustin
authors.forename: Jessica
authors.initials: J
authors.lastname: Lizarde
authors.forename: Albert V
authors.initials: AV
authors.lastname: Mesa
authors.forename: Jorge C
authors.initials: JC
authors.lastname: Macedo
authors.forename: John
authors.initials: J
authors.lastname: Ravera
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Tokita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods; D001943:Breast Neoplasms / Q000737:chemistry* / Q000208:ethnology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D016009:Chi-Square Distribution; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000517:prevention & control; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012044:Regression Analysis; D018709:Statistics, Nonparametric; D015996:Survival Rate
chemical_list: D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone